Table 1.
Epidemiological Characteristics of the Study Population.
| Total (n = 97) | HIV+ (n = 29) | HIV+/HCV−(n = 32) | HIV+/HCV+ (n = 36) | P | |
|---|---|---|---|---|---|
| Median Age, years [median (IQR)] | 50 (45–54) | 48 (38–54) | 52 (48–55) | 52 (44–54) | 0.372 |
| Weight, kg [median (IQR)] | 70 (61–80) | 75 (67–84) | 76 (64–83) | 62 (55–73) | 0.002* |
| Height, cm [median (IQR)] | 168 (162–174) | 168 (163–173) | 169 (164–175) | 167 (160–174) | 0.512 |
| BMI, kg/m2 [median (IQR)] | 24 (22–27) | 26 (23–28) | 25 (22–28) | 23 (21–25) | 0.012** |
| Male, n (%) | 62 (63.9) | 18 (62.1) | 21 (65.6) | 23 (63.9) | 0.959 |
| Time of HIV infection, years [median (IQR)] | 19.9 (8.8–26.6) |
15.1 (6.1–22.0) |
21.7 (12.2–26.6) |
22.8 (9.5–8.7) |
0.035 *** |
| Transmission route, n (%) | |||||
| IDUs | 41 (42.3) | 0 | 20 (62.5) | 21 (58.3) | 0.017 |
| MSM | 27 (27.8) | 13 (44.8) | 6 (18.8) | 8 (22.2) | |
| MSW | 17 (17.5) | 12 (41.4) | 3 (9.4) | 2 (5.5) | |
| Others | 12 (12.3) | 3 (9.4) | 3 (9.4) | 5 (14.1) | |
| CDC category, n (%) | |||||
| A | 51 (52.5) | 18 (62.1) | 16 (50.0) | 17 (47.2) | 0.219 |
| B | 19 (19.6) | 4 (13.8) | 6 (18.8) | 9 (25.0) | |
| C | 23 (23.7) | 4 (13.8) | 9 (28.1) | 10 (27.8) | |
| Unknown | 4 (4.1) | 3 (10.3) | 1 (3.1) | 0 | |
| cART regimen, n (%) | |||||
| NNRTIs | 30 (30.9) | 8 (27.6) | 13 (40.6) | 9 (25.0) | 0.232 |
| PIs | 10 (10.3) | 2 (6.9) | 4 (12.5) | 4 (11.1) | |
| INIs | 36 (37.1) | 11 (37.9) | 11 (34.4) | 14 (38.9) | |
| Dual therapy | 16 (16.5) | 6 (20.7) | 4 (12.5) | 6 (16.7) | |
| Monotherapy | 5 (5.2) | 2 (6.9) | 0 | 3 (8.3) | |
| CMV Infection, n, (%) | |||||
| Yes | 39 (40.2) | 8 (27.6) | 15 (46.9) | 16 (44.4) | 0.309 |
| No | 29 (29.9) | 12 (41.4) | 6 (18.8) | 11 (30.6) | |
| Unknown | 29 (29.9) | 9 (31.0) | 11 (34.4) | 9 (25.0) | |
| IFNL3 (IL28B) genotype, n (%) | |||||
| CC | 53 (54.6) | 16 (55.2) | 24 (75.0%) | 13 (37.1) | 0.008 |
| Non-CC | 43 (44.4) | 13 (44.8) | 8 (25.0) | 22 (61.9) | |
Notes: BMI, body mass index; HIV, human immunodeficiency virus; HCV, hepatitis C virus; IDUs, Intravenous Drug Users; MSM, men who have sex with men; MSW, men who have sex with women; CDC, Centers for Disease Control and Prevention classification system for HIV infection; cART, combined antiretroviral therapy; NRTIs, nucleoside analogue reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; INIs, integrase inhibitors; CMV, cytomegalovirus; %, percentage; IQR, interquartile range. CC: CC genotype. *Comparison of weight between groups performed by Mann-Whitney test: HIV+ group vs. HIV+/HCV+ group, P = 0.001; HIV+/HCV− group vs. HIV+/HCV+ group, P = 0.005. **Comparison of BMI between groups performed by Mann-Whitney test: HIV+ group vs. HIV+/HCV+ group, P = 004; HIV+/HCV− group vs. HIV+/HCV+ group, P = 0.050.
***Comparison of time of HIV infection between groups performed by Mann-Whitney test: HIV+ group vs. HIV+/HCV− group, P = 0.021; HIV+ group vs. HIV+/HCV+ group, P = 0.026.
Patients: ▪ HIV+ group: HIV-monoinfected patients that had never been in contact with HCV (negative PCR and HCV antibodies).
▪ HIV+/HCV− group: HIV patients who had been exposed to HCV but experienced spontaneous viral clearance during the first 6 months after HCV infection (negative PCR and positive HCV antibodies).
▪ HIV+/HCV+ group: patients with HIV and active HCV-chronic infection naïve to any HCV treatment (positive PCR and HCV antibodies).